FDA approves Amneal’s BLA for Alymsys® (biosimilar bevacizumab)

Apr 13, 2022

Amneal Pharmaceuticals announced that the FDA has approved its BLA for Alymsys® (biosimilar bevacizumab) marking the second of three oncology biosimilar approvals Amneal expects to receive in 2022.  Alymsys® was developed by mAbxience, and its approval is the third biosimilar bevacizumab approved in the US.

Print Page Mail Article